Navigation Links
National Institute of Neurological Disorders and Stroke (NINDS) Stops Enrolling Patients in ARUBA Study Earlier Than Planned
Date:5/10/2013

New York, nY (PRWEB) May 10, 2013

Today the National Institute of Neurological Disorders and Stroke (NINDS) announced that “A Randomized Trial of Unruptured Brain Arteriovenous Malformations” (ARUBA) has stopped enrolling patients because of higher than expected event rates in the interventional therapy arm.

The International Center for Health Outcomes and Innovation Research (InCHOIR) at the Icahn School of Medicine at Mount Sinai is the international data-coordinating center for the trial. “We have discovered that, in an interim analysis of the data collected so far, medical management was superior to interventional therapy for patients with unruptured brain arteriovenous malformations,” said Alan J. Moskowitz, MD, Professor and Vice Chair of Health Evidence and Policy at the Icahn School of Medicine, and Co-Director of InCHOIR). “It is our recommendation that extended follow-up is needed to determine whether these disparities in rates will persist over time.”

The data, analyzed by InCHOIR under the direction of Michael Parides, PhD, Director of the Center for Biostatistics at the Icahn School of Medicine at Mount Sinai, has shown that after a mean follow-up of 33 months, the event rate in the intervention group was more than three times higher than in the medical management group. The analysis included data from 224 participants enrolled in the study’s 39 worldwide sites, in an effort that was coordinated by Ellen Moquete, RN, BSN, Director of Trials Operations at InCHOIR. Originally, the study planned to enroll 400 participants, however, because of the higher than expected event rate in the interventional therapy arm, the ARUBA Data and Safety Monitoring Board has recommended stopping enrollment while continuing to follow those in the study to see if the difference changes over time.

Another key endpoint in the trial is functional status, said Dr. Parides. “Continued follow-up of patients will help determine whether the observed differences in event rates will translate into meaningful long-term differences in patient functioning.”

ARUBA is a randomized, multi-center trial designed to evaluate whether symptomatic medical management improves long-term outcomes of patients with unruptured brain arteriovenous malformations compared to invasive treatment for the composite event of death from any cause or symptomatic stroke. There will be a detailed analysis of the data as well as further results presented at the European Stroke Conference in London on May 31.

The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine is one of the leading medical schools in the United States. The Medical School is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.

The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2011, U.S. News & World Report ranked The Mount Sinai Hospital 16th on its elite Honor Roll of the nation’s top hospitals based on reputation, safety, and other patient-care factors. Of the top 20 hospitals in the United States, Mount Sinai is one of 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.

For more information, visit http://www.mountsinai.org/
Find Mount Sinai on Facebook, Twitter and YouTube.

# # #

Read the full story at http://www.prweb.com/releases/2013/5/prweb10723442.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. MU receives national award for using mind-body approach to improve health
2. International breast health global summit will focus on supportive care and quality of life
3. International conference to explore health of descendants of transatlantic slave trade
4. National poll: Low cost, lifesaving services missing from most older patients health care
5. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
6. Kessler Foundation researchers present at first International Congress on Cognition in MS
7. Dr. Yael Mosse will receive first Nachman Award in Pediatric Oncology at national conference
8. Georgetown physician leads national resveratrol study for Alzheimers disease
9. National initiative launched to change the way biology departments approach undergraduate education
10. Boston researcher, surgical oncologist receives national award
11. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Source ... botanicals and 100 percent pure essential oils, announced the company had a successful visit ... , The annual ECRM event gives companies that work in the nutritional, sports and ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Bionic Sports ... all walks of life, announced it had a successful January ECRM Trade Show in ... in the United States, which allows it to provide its products to all clients ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... boca raton florida (PRWEB) , ... January 20, 2017 , ... ... trial at the Dana Farber Cancer Institute. For Betsy, the clinical trial has ... and her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... CITY, Calif. , Jan. 19, 2017  Abaxis, ... company manufacturing point-of-care blood analysis instruments and consumables for ... conference call to discuss its financial results for the ... The call will be at 4:15 p.m. ET on ... results for the third quarter fiscal year 2017 after ...
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, Inc. ... company specializing in the treatment of non-melanoma skin ... with superficial radiation therapy, today announced that it ... 2016 financial results on Thursday, February 2, 2017 after ... hold a conference call with the investment community ...
(Date:1/19/2017)... LEXINGTON, Massachusetts , January 19, 2017 ... SHPG ) announced that the U.S. Food and Drug ... resubmission of a New Drug Application (NDA) for SHP465, ... being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity ... decision on or around June 20, 2017, the designated ...
Breaking Medicine Technology: